-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since the beginning of this year, License in has been very popular in the pharmaceutical industry
.
A large number of pharmaceutical companies have announced that they will cooperate with other companies in innovative drugs
.
According to incomplete statistics, a total of 11 license in transactions have occurred in domestic pharmaceutical companies in October, and the disclosed transaction amount has exceeded 2.
2 billion US dollars
.
It is worth noting that the author understands that in order to accelerate the development and commercialization of innovative drugs, the cooperation between pharmaceutical companies on innovative drugs is still increasing
.
Since November, a number of pharmaceutical companies have announced that they will join forces to cooperate in innovative drugs in different fields from multiple perspectives
.
For example, on November 10, Tianjing Bio announced that it had reached a product development, production and commercialization cooperation with Jichuan Pharmaceutical on the highly differentiated long-acting recombinant human growth hormone eftansomatropin alfa (eftansomatropin alfa, TJ101)
.
According to the terms of the agreement, Jichuan Pharmaceutical will make an advance payment of RMB 224 million to Tianjing Bio.
After reaching certain development, registration and sales milestones, Tianjing Bio will receive a cumulative milestone payment of up to 1.
792 billion yuan, with the highest total payment.
Up to 2.
016 billion yuan
.
At the same time, Tianjing Bio will share the commercialization income of the product in the Chinese mainland market in accordance with the 50:50 principle, and under this principle will be entitled to an authorization commission that is a low double-digit percentage of annual net sales
.
On November 8, CStone Pharmaceuticals announced that it had signed a cooperation agreement with DotBio Pte.
Ltd, a biotechnology company focused on developing next-generation antibody therapies
.
Through cooperation, the two parties will jointly develop up to three first-in-class or best-in-class next-generation antibody therapies, including multifunctional antibody drugs and antibody-conjugated drugs ("ADC")
.
It is understood that this is the first cooperation project to settle in the global R&D center and industrialization base of CStone Pharmaceuticals.
CStone Pharmaceuticals will guide the design of target combinations based on the desired mechanism of action, and Dote Bio will lead the design and construction of molecules
.
The industry expects that the cooperation will provide preclinical drug candidates for CStone's pipeline 2.
0 strategy and further promote drug R&D and source innovation
.
On November 3, Aoxiang Pharmaceutical issued an announcement stating that it has signed a "Cooperative Development and Commercialization Strategic Cooperation Agreement" with STADA Arzneimittel AG (STADA") approved by the board of directors, and the two parties focus on the future global For the development prospects of the pharmaceutical industry, we will carry out long-term and multi-faceted cooperation on the joint development of chemical generic pharmaceutical preparations and global marketing
.
At present, the R&D investment budget for the first phase of the selected projects of the two parties is 23.
5 million euros, and the countries in the cooperation area will be jointly borne by the two parties (50%/50%)
.
The industry predicts that with the favorable review and approval of innovative drugs and the benefit of medical insurance payments, more and more companies will invest in innovative drug research and development through the License in model, and continue to enrich the R&D pipeline
.
It is worth noting that, according to the current development trend, companies with strong R&D capabilities in the future, especially R&D focused on a certain disease field, as well as companies with drug declaration capabilities and excellent drug commercialization capabilities, are expected to become License in the future The main driving force of development
.
.
A large number of pharmaceutical companies have announced that they will cooperate with other companies in innovative drugs
.
According to incomplete statistics, a total of 11 license in transactions have occurred in domestic pharmaceutical companies in October, and the disclosed transaction amount has exceeded 2.
2 billion US dollars
.
It is worth noting that the author understands that in order to accelerate the development and commercialization of innovative drugs, the cooperation between pharmaceutical companies on innovative drugs is still increasing
.
Since November, a number of pharmaceutical companies have announced that they will join forces to cooperate in innovative drugs in different fields from multiple perspectives
.
For example, on November 10, Tianjing Bio announced that it had reached a product development, production and commercialization cooperation with Jichuan Pharmaceutical on the highly differentiated long-acting recombinant human growth hormone eftansomatropin alfa (eftansomatropin alfa, TJ101)
.
According to the terms of the agreement, Jichuan Pharmaceutical will make an advance payment of RMB 224 million to Tianjing Bio.
After reaching certain development, registration and sales milestones, Tianjing Bio will receive a cumulative milestone payment of up to 1.
792 billion yuan, with the highest total payment.
Up to 2.
016 billion yuan
.
At the same time, Tianjing Bio will share the commercialization income of the product in the Chinese mainland market in accordance with the 50:50 principle, and under this principle will be entitled to an authorization commission that is a low double-digit percentage of annual net sales
.
On November 8, CStone Pharmaceuticals announced that it had signed a cooperation agreement with DotBio Pte.
Ltd, a biotechnology company focused on developing next-generation antibody therapies
.
Through cooperation, the two parties will jointly develop up to three first-in-class or best-in-class next-generation antibody therapies, including multifunctional antibody drugs and antibody-conjugated drugs ("ADC")
.
It is understood that this is the first cooperation project to settle in the global R&D center and industrialization base of CStone Pharmaceuticals.
CStone Pharmaceuticals will guide the design of target combinations based on the desired mechanism of action, and Dote Bio will lead the design and construction of molecules
.
The industry expects that the cooperation will provide preclinical drug candidates for CStone's pipeline 2.
0 strategy and further promote drug R&D and source innovation
.
On November 3, Aoxiang Pharmaceutical issued an announcement stating that it has signed a "Cooperative Development and Commercialization Strategic Cooperation Agreement" with STADA Arzneimittel AG (STADA") approved by the board of directors, and the two parties focus on the future global For the development prospects of the pharmaceutical industry, we will carry out long-term and multi-faceted cooperation on the joint development of chemical generic pharmaceutical preparations and global marketing
.
At present, the R&D investment budget for the first phase of the selected projects of the two parties is 23.
5 million euros, and the countries in the cooperation area will be jointly borne by the two parties (50%/50%)
.
The industry predicts that with the favorable review and approval of innovative drugs and the benefit of medical insurance payments, more and more companies will invest in innovative drug research and development through the License in model, and continue to enrich the R&D pipeline
.
It is worth noting that, according to the current development trend, companies with strong R&D capabilities in the future, especially R&D focused on a certain disease field, as well as companies with drug declaration capabilities and excellent drug commercialization capabilities, are expected to become License in the future The main driving force of development
.
